Head-To-Head Analysis: Marker Therapeutics (NASDAQ:MRKR) and Molecular Partners (NASDAQ:MOLN)

Marker Therapeutics (NASDAQ:MRKR) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Marker Therapeutics and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
Molecular Partners	N/A	-68.36%	-54.82%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Marker Therapeutics and Molecular Partners, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	1	2	0	2.25
Molecular Partners	1	1	2	0	2.25

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 952.63%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 110.27%. Given Marker Therapeutics’ higher probable upside, equities analysts clearly believe Marker Therapeutics is more favorable than Molecular Partners.

Volatility & Risk

Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Institutional & Insider Ownership

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Marker Therapeutics and Molecular Partners”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55 million	4.46	-$12.16 million	($0.41)	-2.32
Molecular Partners	$5.65 million	28.47	-$74.41 million	($1.71)	-2.33

Marker Therapeutics has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Marker Therapeutics beats Molecular Partners on 7 of the 11 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.